FSCN1 and ductal breast carcinoma in situ: To define the potential role of FSCN1 in the progression of mammary carcinoma, we performed IHC analysis to assess the expression of FSCN1 on 125 UDH, 104 DCIS, and 467 IDC tissue samples (Fig. 1A–D).